|
Gene: FAM214B |
Gene summary for FAM214B |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAM214B | Gene ID | 80256 |
Gene name | family with sequence similarity 214 member B | |
Gene Alias | KIAA1539 | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q7L5A3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80256 | FAM214B | C21 | Human | Oral cavity | OSCC | 4.61e-10 | 3.31e-01 | 0.2678 |
80256 | FAM214B | C30 | Human | Oral cavity | OSCC | 3.58e-18 | 1.08e+00 | 0.3055 |
80256 | FAM214B | C38 | Human | Oral cavity | OSCC | 3.43e-02 | 4.30e-01 | 0.172 |
80256 | FAM214B | C51 | Human | Oral cavity | OSCC | 9.69e-04 | 3.81e-01 | 0.2674 |
80256 | FAM214B | C06 | Human | Oral cavity | OSCC | 1.08e-09 | 1.18e+00 | 0.2699 |
80256 | FAM214B | SYSMH1 | Human | Oral cavity | OSCC | 2.28e-09 | 1.97e-01 | 0.1127 |
80256 | FAM214B | SYSMH3 | Human | Oral cavity | OSCC | 2.20e-10 | 3.11e-01 | 0.2442 |
80256 | FAM214B | SYSMH6 | Human | Oral cavity | OSCC | 4.25e-04 | 1.19e-01 | 0.1275 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM214B | SNV | Missense_Mutation | rs746473903 | c.1205N>T | p.Pro402Leu | p.P402L | Q7L5A3 | protein_coding | deleterious(0.01) | possibly_damaging(0.888) | TCGA-G4-6295-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | rs747386620 | c.725G>A | p.Arg242Gln | p.R242Q | Q7L5A3 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
FAM214B | SNV | Missense_Mutation | rs778936766 | c.1561N>A | p.Glu521Lys | p.E521K | Q7L5A3 | protein_coding | deleterious(0.05) | probably_damaging(0.936) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | novel | c.1234N>G | p.Asn412Asp | p.N412D | Q7L5A3 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-DC-6157-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FAM214B | insertion | Frame_Shift_Ins | rs775865641 | c.1002dupC | p.Ser335GlnfsTer19 | p.S335Qfs*19 | Q7L5A3 | protein_coding | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | ||
FAM214B | insertion | Frame_Shift_Ins | rs775865641 | c.1002dupC | p.Ser335GlnfsTer19 | p.S335Qfs*19 | Q7L5A3 | protein_coding | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
FAM214B | SNV | Missense_Mutation | novel | c.536N>A | p.Pro179His | p.P179H | Q7L5A3 | protein_coding | deleterious_low_confidence(0.04) | benign(0.219) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | novel | c.1592N>G | p.Asn531Ser | p.N531S | Q7L5A3 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | rs780231569 | c.1379N>A | p.Arg460His | p.R460H | Q7L5A3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | novel | c.1150N>T | p.His384Tyr | p.H384Y | Q7L5A3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |